Med-Fine Capital
幂方健康基金
elsewhere's corpus does not cover Med-Fine Capital as a subject. The bundle contains only passing mentions of Med-Fine Capital (幂方健康基金) as a co-investor alongside Gaorong Capital (高榕创投) in follow-on investments into AllinkBio, a biotech company developing bispecific antibodies and ADCs . No entity card, founding details, team composition, or strategy description for Med-Fine Capital itself appears in the retrieved material.
AI-generated — may contain errors, please verify.
Coverage
5Y News｜Aikelian Biotechnology Completes $68.7 Million Funding Round
Aikelian Biotech has successfully completed an oversubscribed $68.7 million funding round.
Gaorong Report · 2025 | Innovative Drugs, Agri-Tech, AI Content Platforms Close Funding Rounds; Gaorong Earns Multiple Accolades
Innovation as the sail, hard work as the oar.
Anlink Bio Completes $42 Million Series A Round to Accelerate Global Development of Bispecific Antibodies and ADC Pipeline
Achieving a rapid transition from preclinical to clinical stages.
BlueRun Ventures Leads AllinkBio's $42 Million Series A Round | BlueRun Ventures
Accelerating Global Development of Bispecific Antibodies and ADC Products
